Holen Sie sich die Stockscreener-App
13.30
1.29%
0.17
Handel nachbörslich:
13.45
0.15
+1.13%
Schlusskurs vom Vortag:
$13.13
Offen:
$13.17
24-Stunden-Volumen:
1.94M
Relative Volume:
0.41
Marktkapitalisierung:
$1.57B
Einnahmen:
$67.67M
Nettoeinkommen (Verlust:
$-412.69M
KGV:
-3.4757
EPS:
-3.8266
Netto-Cashflow:
$-395.87M
1W Leistung:
+14.16%
1M Leistung:
-1.04%
6M Leistung:
-35.25%
1J Leistung:
+100.60%
1-Tages-Spanne:
$13.17
$13.72
1-Wochen-Bereich:
$11.87
$13.72
52-Wochen-Spanne:
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
13.30 | 1.55B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-11-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Intellia Therapeutics Announces Inducement Grants - National Today
Intellia Grants 67,150 RSUs to 13 New Hires - National Today
Intellia Therapeutics, Inc. (NTLA) Stock Price, News, Quote & History - Yahoo! Finance Canada
13 new Intellia employees get 67,150 stock units over 3 years - Stock Titan
Gene Editing Market Set to Boom Rapidly by 2033 |CRISPR - openPR.com
Intellia Therapeutics Stock Price Forecast. Should You Buy NTLA? - StockInvest.us
Trading Systems Reacting to (NTLA) Volatility - news.stocktradersdaily.com
Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects - TechStock²
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Intellia Therapeutics, Inc. (NTLA) Stock Forecasts - Yahoo Finance
Trending Industry Today: Intellia Therapeutics Leads Losses In Gene Editing Stocks - Moomoo
Intellia Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Intellia Therapeutics (NTLA) — Vanguard disaggregates holdings, parent reports 0 shares - Stock Titan
Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to Strong-Buy at Truist Financial - MarketBeat
Risk Hedge: Is Intellia Therapeutics Inc a top pick in the sectorQuarterly Market Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
Bank of America Securities Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA) - The Globe and Mail
Investors in Intellia Therapeutics, Inc. Should Contact Levi & Ko - The National Law Review
Aug Drivers: Does Intellia Therapeutics Inc have a sustainable dividendQuarterly Growth Report & Smart Swing Trading Alerts - baoquankhu1.vn
Hudson Bay Capital Management LP Sells 235,000 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
NTLA SEC FilingsIntellia Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Intellia rises on Q4 earnings & revenue beat, focuses on pipeline - MSN
Intellia jumps as FDA lifts clinical hold on Nex-Z for ATTR-CM - MSN
How Intellia Therapeutics Inc. (NTLA) Affects Rotational Strategy Timing - Stock Traders Daily
Intellia Therapeutics’ stock rocked by patient death in gene therapy trial - MSN
Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger ‘Buy’ - MSN
NTLA Technical Analysis | Trend, Signals & Chart Patterns | INTELLIA THERAPEUTICS INC (NASDAQ:NTLA) - ChartMill
Best CRISPR Companies for 2026 and How to Invest in Them - The Motley Fool
Intellia Therapeutics, Inc. $NTLA Position Trimmed by Granahan Investment Management LLC - MarketBeat
Farallon Capital Management LLC Purchases Shares of 607,200 Intellia Therapeutics, Inc. $NTLA - MarketBeat
KalVista Pharmaceuticals: Has Potential But With Caveats (NASDAQ:KALV) - Seeking Alpha
Lost Money on Intellia Therapeutics, Inc.(NTLA)? Join Class Acti - GuruFocus
Is Intellia Therapeutics (NTLA) Turning Regulatory Scrutiny Into a Strategic Edge in Gene Editing? - Sahm
Intellia Therapeutics at Leerink Global Healthcare Conference: Gene Editing Prospects - Investing.com Canada
Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory (NASDAQ:NTLA) - Seeking Alpha
NTLA: Mid-year Phase 3 data could enable a first-in-class, one-time gene editing launch for HAE - TradingView
(NTLA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Cathie Wood's Intellia Therapeutics Surges 47%: Is It Too Late to Invest? - Intellectia AI
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy? - Nasdaq
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Hold Lift And New Gene Editing Data - Sahm
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen - MarketBeat
Intellia Therapeutics Q4 2025 earnings preview - MSN
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD - Stocktwits
Analysts Offer Insights on Healthcare Companies: Rigel (RIGL), Arcturus Therapeutics (ARCT) and Intellia Therapeutics (NTLA) - The Globe and Mail
Is Intellia Therapeutics (NTLA) Pricing Look Interesting After Strong Year-To-Date Share Gain? - simplywall.st
A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound - Yahoo Finance
Amova Asset Management Americas Inc. Cuts Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat
ARK Investment Management LLC Trims Stake in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Jones Trading Upgrades Intellia Therapeutics (NTLA) - Nasdaq
FDA again targets GLP-1 compounders; Intellia to restart heart disease trial - BioPharma Dive
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Intellia Therapeutics Inc-Aktie (NTLA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Clark Eliana | EVP, Chief Technical Officer |
Mar 02 '26 |
Sale |
13.78 |
607 |
8,364 |
93,864 |
| LEONARD JOHN M | President and CEO |
Jan 05 '26 |
Sale |
9.21 |
34,146 |
314,485 |
1,013,339 |
| Schultes Birgit C | EVP, Chief Scientific Officer |
Jan 05 '26 |
Sale |
9.21 |
8,508 |
78,359 |
98,533 |
| BASTA JAMES | EVP, General Counsel |
Jan 05 '26 |
Sale |
9.21 |
10,397 |
95,756 |
101,528 |
| Cohen Fred E | Director |
Jan 05 '26 |
Buy |
9.35 |
150,000 |
1,402,500 |
207,453 |
| Lebwohl David | EVP, Chief Medical Officer |
Jan 05 '26 |
Sale |
9.21 |
11,903 |
109,627 |
121,249 |
| Clark Eliana | EVP, Chief Technical Officer |
Jan 05 '26 |
Sale |
9.21 |
9,515 |
87,633 |
87,118 |
| Dulac Edward J III | EVP, Chief Financial Officer |
Jan 05 '26 |
Sale |
9.21 |
6,379 |
58,751 |
99,683 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 05 '26 |
Sale |
9.21 |
2,989 |
27,529 |
52,277 |
| LEONARD JOHN M | President and CEO |
Dec 11 '25 |
Option Exercise |
6.83 |
49,959 |
341,220 |
1,127,074 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):